03Aug 2021
Upadacitinib in Active Ankylosing Spondylitis: 1‐Year Results From the Double‐Blind, Placebo‐Controlled SELECT‐AXIS 1 Study and Open‐Label Extension

Upadacitinib in Active Ankylosing Spondylitis: 1‐Year Results From the Double‐Blind, Placebo‐Controlled SELECT‐AXIS 1 Study and Open‐Label Extension

To report efficacy and safety of upadacitinib through 1 year in patients with ankylosing spondylitis (AS). In the SELECT‐AXIS 1 study, adults with active AS and inadequate response to non‐steroidal anti‐inflammatory drugs were randomized to upadacitinib 15 mg once daily (QD) or placebo. At week 14, patients continued in the open‐label extension and received upadacitinib up to week 104; reported here are interim data up to week 64...

  • #family health

Like

Save

Share